In vitro cytotoxicity and immune response
| Patient no. . | Peptide(s) . | Cytotoxicity (%) E:T 30:1* . | Maximum of tetramer/pentamer+/CD8+ T cells after adoptive transfer, %* . | Day of maximum tetramer/pentamer response . |
|---|---|---|---|---|
| 1 | BCR-ABL A3/B8 | 54 (Bcr-Abl A3) | 1.7 (Bcr-Abl A3) | 360 |
| 2 | BCR-ABL B8, PR1 | — | 1.39 (PR1) | 112 |
| 3 | BCR-ABL B8, PR1 | 51 (Bcr-Abl B8) | 1.7 (Bcr-Abl B8) | 56 |
| 4 | PR1 | — | 2.4 | 122 |
| 5 | PR1 | 59 | 0.13 | 49 |
| 6 | PR1 | 48 | 0.14 | 112 |
| 7 | PR1 | — | 0.6 | 63 |
| 8 | BCR-ABL A3/11 | — | 3.9 | 35 |
| 9 | BCR-ABL A11 | — | 4.9 | 140 |
| 10 | BCR-ABL B8 | — | 10.2 | 42 |
| 11 | BCR-ABL A3, PR1, WT1 | 48 (Bcr-Abl A3) | 3.6 (Bcr-Abl A3) | 112 |
| 12 | PR1, WT1 | 35 (PR1) | 1.6 (WT1) | 180 |
| 13 | WT1 (A24) | — | 1.6 | 40 |
| 14 | WT1, PR1 | 46 (WT1) | 2.7 (WT1) | 154 |
| Patient no. . | Peptide(s) . | Cytotoxicity (%) E:T 30:1* . | Maximum of tetramer/pentamer+/CD8+ T cells after adoptive transfer, %* . | Day of maximum tetramer/pentamer response . |
|---|---|---|---|---|
| 1 | BCR-ABL A3/B8 | 54 (Bcr-Abl A3) | 1.7 (Bcr-Abl A3) | 360 |
| 2 | BCR-ABL B8, PR1 | — | 1.39 (PR1) | 112 |
| 3 | BCR-ABL B8, PR1 | 51 (Bcr-Abl B8) | 1.7 (Bcr-Abl B8) | 56 |
| 4 | PR1 | — | 2.4 | 122 |
| 5 | PR1 | 59 | 0.13 | 49 |
| 6 | PR1 | 48 | 0.14 | 112 |
| 7 | PR1 | — | 0.6 | 63 |
| 8 | BCR-ABL A3/11 | — | 3.9 | 35 |
| 9 | BCR-ABL A11 | — | 4.9 | 140 |
| 10 | BCR-ABL B8 | — | 10.2 | 42 |
| 11 | BCR-ABL A3, PR1, WT1 | 48 (Bcr-Abl A3) | 3.6 (Bcr-Abl A3) | 112 |
| 12 | PR1, WT1 | 35 (PR1) | 1.6 (WT1) | 180 |
| 13 | WT1 (A24) | — | 1.6 | 40 |
| 14 | WT1, PR1 | 46 (WT1) | 2.7 (WT1) | 154 |
E:T indicates effector/target ratio; and —, not detectable.
Specificity of cytotoxic response or HLA+/peptide+ CD8+ T cells detectable by flow cytometry is provided in parentheses whenever CTL with specificities for > 1 peptide were infused.